DILI occurs through direct toxicity (acetaminophen, statins) or idiosyncratic reactions (antibiotics, NSAIDs). Hepatocellular injury produces ALT elevation; cholestatic patterns involve bile duct obstruction or hepatic transport dysfunction. Immune-mediated mechanisms cause hypersensitivity reactions.
Your foundation in hepatocellular injury mechanisms gave you the basic toolkit: mitochondrial dysfunction, oxidative stress, and programmed cell death pathways. Your background in cytochrome P450 metabolism adds the critical pharmacological layer — drugs are not usually toxic in their parent form, but their CYP450-generated metabolites often are. Drug-induced liver injury (DILI) is where these two frameworks converge.
The clearest conceptual divide in DILI is between intrinsic (predictable) and idiosyncratic (unpredictable) injury. Intrinsic DILI is dose-dependent: anyone who takes enough acetaminophen will develop liver injury. The mechanism is CYP2E1-mediated conversion of acetaminophen to NAPQI (N-acetyl-p-benzoquinone imine), a reactive electrophile that depletes glutathione and then attacks cellular proteins and mitochondria. At therapeutic doses, glutathione neutralizes NAPQI efficiently. At overdose, glutathione is exhausted, NAPQI accumulates, and hepatocyte death follows in the centrilobular zone where CYP2E1 expression is highest. This is why N-acetylcysteine (a glutathione precursor) is the antidote — it replenishes the defense that the overdose overwhelmed.
Idiosyncratic DILI is more treacherous because it affects only rare individuals at normal therapeutic doses and cannot be predicted from dose alone. Mechanistically, idiosyncratic DILI typically involves two hits: the drug or its metabolite acts as a hapten, binding to liver proteins and triggering immune recognition, while simultaneously causing enough cell stress to activate danger signals that lower the threshold for immune attack. The immune system mounts a response against drug-modified liver proteins as if they were foreign. This explains why idiosyncratic reactions often occur with re-exposure at lower latency and greater severity — immunologic memory has been established. Amoxicillin-clavulanate is one of the most common culprits.
The hepatocellular versus cholestatic distinction reflects which liver function is primarily disrupted. Hepatocellular injury (elevated ALT, AST) means the hepatocytes themselves are dying — their cytoplasmic enzymes leak into blood. Cholestatic injury (elevated alkaline phosphatase and bilirubin, but modest aminotransferase rise) means bile is not flowing normally: either the bile ducts are damaged or the hepatic transporters that excrete bile into the canaliculi are impaired. Some drugs produce mixed patterns. Identifying the pattern matters clinically because it guides prognosis — pure hepatocellular patterns with high aminotransferase elevations carry greater risk of acute liver failure than cholestatic patterns, which tend to be self-limiting even if resolution takes months.
No topics depend on this one yet.